Association of anti-IL-12/23 biologic agents ustekinumab and briakinumab with major adverse cardiovascular events

  • T. Tzellos, A. Kyrgidis, A. Trigoni, C.C. Zouboulis
  • Journal of the European Academy of Dermatology and Venereology, March 2013, Wiley
  • DOI: 10.1111/jdv.12126

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Dr Thrasivoulos Tzellos